Pzena Investment Management LLC Takes $42.15 Million Position in Teleflex Incorporated $TFX

Pzena Investment Management LLC purchased a new stake in Teleflex Incorporated (NYSE:TFX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 356,107 shares of the medical technology company’s stock, valued at approximately $42,149,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Thompson Investment Management Inc. raised its position in Teleflex by 2.1% in the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock worth $588,000 after purchasing an additional 100 shares during the last quarter. CX Institutional grew its holdings in Teleflex by 14.7% during the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company’s stock worth $103,000 after acquiring an additional 112 shares during the period. Signaturefd LLC grew its holdings in shares of Teleflex by 38.3% in the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock valued at $60,000 after buying an additional 120 shares during the period. Empirical Finance LLC grew its holdings in shares of Teleflex by 7.9% in the 1st quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock valued at $234,000 after buying an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in shares of Teleflex by 30.2% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock valued at $77,000 after buying an additional 129 shares during the period. 95.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Liam Kelly acquired 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 5th. The stock was acquired at an average price of $115.07 per share, with a total value of $172,605.00. Following the purchase, the chief executive officer directly owned 45,267 shares in the company, valued at approximately $5,208,873.69. This trade represents a 3.43% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gretchen R. Haggerty purchased 500 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were acquired at an average cost of $114.75 per share, with a total value of $57,375.00. Following the purchase, the director directly owned 6,305 shares of the company’s stock, valued at approximately $723,498.75. The trade was a 8.61% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 5,500 shares of company stock worth $633,590 over the last 90 days. Insiders own 1.40% of the company’s stock.

Wall Street Analysts Forecast Growth

TFX has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their target price on shares of Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a research note on Friday, August 1st. Mizuho boosted their price target on shares of Teleflex from $130.00 to $135.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Zacks Research cut shares of Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Wall Street Zen cut shares of Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Finally, Wells Fargo & Company cut their price target on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Teleflex presently has a consensus rating of “Reduce” and an average target price of $141.57.

Teleflex Stock Down 4.1%

Teleflex stock opened at $119.54 on Monday. The stock has a market cap of $5.28 billion, a P/E ratio of 28.13, a P/E/G ratio of 1.67 and a beta of 1.05. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a twelve month low of $108.90 and a twelve month high of $241.41. The company’s 50-day moving average price is $124.30 and its two-hundred day moving average price is $124.07.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.36 by $0.37. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The firm had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. During the same quarter in the prior year, the business posted $3.42 EPS. The business’s revenue was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, analysts expect that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 15th were paid a $0.34 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $1.36 annualized dividend and a yield of 1.1%. Teleflex’s dividend payout ratio is presently 32.00%.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.